(Q44832153)

6 December 2017

title

Suppression of B cell activation by cyclosporin A, FK506 and rapamycin (English)

1 reference

https://api.crossref.org/works/10.1002/EJI.1830201017

2 November 2022

1 reference

1 reference

https://api.crossref.org/works/10.1002/EJI.1830201017

2 November 2022

author name string

Boltz RC Jr

2

1 reference

6 December 2017

L. S. Wicker

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1700753

2 November 2022

R. C. Boltz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1700753

2 November 2022

V. Matt

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1700753

2 November 2022

E. A. Nichols

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1700753

2 November 2022

L. B. Peterson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1700753

2 November 2022

N. H. Sigal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1700753

2 November 2022

language of work or name

English

0 references

publication date

1 October 1990

1 reference

full work available at URL

6 December 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Feji.1830201017

1 reference

https://api.crossref.org/works/10.1002/EJI.1830201017

https://onlinelibrary.wiley.com/doi/full/10.1002/eji.1830201017

2 November 2022

1 reference

https://api.crossref.org/works/10.1002/EJI.1830201017

European Journal of Immunology

2 November 2022

published in

1 reference

6 December 2017

volume

20

1 reference

6 December 2017

issue

10

1 reference

6 December 2017

page(s)

2277-2283

1 reference

FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

Stimulation of lymphokine release from T lymphoblasts. Requirement for mRNA synthesis and inhibition by cyclosporin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

Induction of Interleukin 2 Messenger RNA Inhibited by Cyclosporin A

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

FK 506 for liver, kidney, and pancreas transplantation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

Cyclosporine-sensitive and cyclosporine-insensitive modes of B cell stimulation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

The mechanism of action of the immunosuppressive drug FK-506.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

Inhibition of the immune response by rapamycin, a new antifungal antibiotic

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

Rapamycin for immunosuppression in organ allografting.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

Human brain tumor xenografts in nude mice as a chemotherapy model.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

Large, activated B cells are the primary B-cell target of 8-bromoguanosine and 8-mercaptoguanosine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

Inductive and differentiative signals delivered by C8-substituted guanine ribonucleosides

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

B lymphocyte receptors and polyphosphoinositide degradation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

Cell-cycle control in lymphocyte stimulation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

Cyclophilin: a specific cytosolic binding protein for cyclosporin A

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase

1 reference

https://api.crossref.org/works/10.1002%2FEJI.1830201017

7 January 2021

Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation

22

1 reference

https://api.crossref.org/works/10.1002/EJI.1830201017

2 November 2022

Identifiers

1 reference

6 December 2017

1 reference